10c target in 12 month , page-2

very quite at the moment in IMU thread.

Today I bought one small bag of popping candy to feel the upcoming "popping vitamin", honestly the feeling is quite good. I believe this kind of technology is just what the market demands.Today I also experience "little bit hard to swallow " when I take one caps of Vitamin. Later on I find out the capsule is nearly 2cm long, no wander.

Although at my age, I actually donot think swallowing is a big problem for me, I do agree the huge potential from "Lower dose of drugs required", "Reduces drug side effects," more importantly IMV, I think the drug can be absorbed into blood sys very quick, which is an advantage for Pain and Inflammation drugs.

Although my average cost of IMU is much higher than 0.8c , I am confident that the market will realize the huge upside potential of IMU, The key reason for me to invest on IMU is the excellent result from the "LC201 Phase I Results: Ibuprofen (Nurofen) !" ----"Faster uptake"

More important reason is there will be substantial positive news flow coming.

Vitamin D could be the first, followed by license agreement for LC200, LC201 Q313 as scheduled. (Q3 2013)

Then "Develop a pharmaceutically stable Linguet drug for Apomorphine Q413" (Q4, 2014)


Value drivers:



Platform allows drugs in tablet form to be delivered straight into the blood
stream via the mouth reducing side effects of absorption in the stomach and
increasing time of drug effectiveness"
• EU registration for prescription level VitD tablet Q114 (early revenues)"
• License agreement for manufacture and distribution of VitD Q114"
• Complete development and clinical trials of pain products LC200 and LC201"
• Enter into MOU around license agreement for LC200, LC201 Q313"
• Patent family extended as new R&D completed Q313-Q214"
• Develop a pharmaceutically stable Linguet drug for Apomorphine Q413"
• Opportunity for big pharma deal similar to, for example Acrux (ASX: ACR)"